Skip to main content
Aurobindo Pharma Ltd. logo

Aurobindo Pharma Ltd. — Investor Relations & Filings

Ticker · AUROPHARMA ISIN · INE406A01037 LEI · 335800G4T2A353RDGM23 BSE.NS Manufacturing
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2026-05-23 Report Publication Anno…
Country IN India
Listing BSE.NS AUROPHARMA

About Aurobindo Pharma Ltd.

https://www.aurobindo.com/

Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 89% confidence The document is a brief notice to the stock exchanges stating that the company has published its quarterly and full‐year financial results in newspaper advertisements and enclosing copies of those ads. It does not itself contain any financial data or detailed results—it simply announces the publication of the report. Under the “menu vs. meal” rule, this is an announcement that a report has been published, making it a Report Publication Announcement (RPA).
2026-05-23 English
Submission of copies of financial results published in newspapers.
Report Publication Announcement Classification · 85% confidence The document is a brief letter from the company secretary to stock exchanges stating that newspaper advertisements containing the financial results for the quarter and year ended March 31, 2026, have been published and are enclosed. It contains no substantive financial data itself but simply announces the publication of the results. According to the “menu vs meal” rule, this is a Report Publication Announcement (RPA).
2026-05-23 English
Intimation of incorporation of a new stepdown subsidiary in France.
Regulatory Filings Classification · 82% confidence The document is a statutory disclosure under Regulation 30 of SEBI listing rules, notifying stock exchanges of the incorporation of a wholly-owned step-down subsidiary and providing details of share subscription and capital. It is not a full financial report, management presentation, dividend notice, or proxy. It is a routine regulatory announcement under listing obligations and best fits the generic Regulatory Filings (RNS) category.
2026-05-22 English
Acquisition
Regulatory Filings Classification · 94% confidence The document is a compliance announcement under Regulation 30 of the SEBI (LODR) Regulations notifying the exchange of incorporation of a new wholly owned subsidiary. It is a regulatory disclosure to the stock exchanges, not a full financial report, earnings release, or corporate governance document. It fits the general category of a regulatory filing/disclosure announcement. Therefore, it is classified as RNS (Regulatory Filings).
2026-05-22 English
Submission of the Financial Results for the year ended March 31, 2026
Interim / Quarterly Report Classification · 86% confidence The document is a board-approved publishing of the Company’s Audited Financial Results under SEBI Reg.33, containing full standalone and consolidated statements (P&L, Balance Sheet, Cash Flows) and notes for the quarter and year ended March 31, 2026. It is not merely a summary highlights release (so not ER), nor a full Annual Report package (no MD&A, corporate overview chapters), nor a simple publication announcement (RPA). It is a comprehensive interim/quarterly results filing with substantive financial data and thus falls under “Interim / Quarterly Report” (IR). FY 2026
2026-05-21 English
Appointment
Regulatory Filings Classification · 78% confidence The document is a stock exchange filing under SEBI Listing Regulations notifying the re-appointment of the company’s internal auditor. It is not a financial report nor a proxy statement, nor a management discussion, but a regulatory compliance announcement relating to corporate governance disclosures. It does not contain financial statements or financial data and serves to inform the exchanges of a Board decision. This fits the ‘Regulatory Filings’ (RNS) category as a general compliance announcement.
2026-05-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.